# PRKACG

## Overview
The PRKACG gene encodes the gamma isoform of the catalytic subunit of protein kinase A (PKA), a serine/threonine kinase that plays a pivotal role in cellular signaling pathways. This protein is integral to the regulation of cyclic adenosine monophosphate (cAMP) levels, influencing various cellular processes such as metabolism, gene expression, and cell cycle progression. The gamma catalytic subunit of PKA, encoded by PRKACG, is involved in the phosphorylation of substrate proteins, which is essential for maintaining cellular homeostasis and proper platelet function. Mutations in PRKACG have been associated with macrothrombocytopenia, a condition characterized by abnormally large platelets and a low platelet count, underscoring the gene's clinical significance in hematological disorders (Manchev2014A; Søberg2018The).

## Function
The PRKACG gene encodes the gamma isoform of the catalytic subunit of protein kinase A (PKA), a key player in various cellular processes. In healthy human cells, PKA is crucial for regulating cyclic adenosine monophosphate (cAMP) levels, a vital signaling molecule. PKA modulates cAMP levels by activating phosphodiesterases, which degrade cAMP into AMP, and by inhibiting adenylyl cyclase, thereby reducing cAMP synthesis from ATP. This regulation is part of a feedback mechanism essential for maintaining cellular homeostasis (Manchev2014A).

PRKACG is also involved in the phosphorylation of substrate proteins, such as filamin A (FLNa), which is important for protecting FLNa from proteolysis. In megakaryocytes and platelets, PRKACG-mediated phosphorylation of FLNa is crucial for maintaining its levels, which is essential for proper platelet formation and function (Manchev2014A). The protein's activity is observed in both the cytoplasm and nucleus, where it influences various cellular functions, including metabolism, gene expression, and cell cycle progression. Through these molecular activities, PRKACG plays a significant role in cell biology and contributes to the organismal outcomes related to platelet biogenesis and function (Manchev2014A).

## Clinical Significance
Mutations in the PRKACG gene, which encodes the gamma catalytic subunit of protein kinase A (PKA), have been linked to a form of macrothrombocytopenia. This condition is characterized by the presence of abnormally large platelets and a low platelet count. A specific germ-line mutation, c.222C>G, resulting in a p.74Ile>Met substitution, has been identified as a cause of this autosomal recessive disorder. Patients with this mutation exhibit defects in proplatelet formation and platelet activation, leading to a bleeding tendency (Manchev2014A). 

The mutation affects the phosphorylation of filamin A (FLNa), which is crucial for platelet function, and results in higher intracellular levels of cAMP in platelets, indicating altered PKA activity. This leads to defective proplatelet formation and larger platelet-like structures, which are hallmarks of the condition (Manchev2014A). Despite these abnormalities, megakaryocyte differentiation and ploidization remain unaffected, suggesting that the mutation specifically disrupts platelet formation and function without altering the overall development of megakaryocytes (Manchev2014A). 

These findings highlight the critical role of PRKACG in maintaining normal platelet size and function, and its mutation can lead to significant hematological disorders.

## Interactions
The PRKACG gene encodes the gamma catalytic subunit of protein kinase A (PKA), which is involved in various protein interactions crucial for cellular processes. The PKA catalytic subunit interacts with regulatory subunits RI and RII, which are essential for its localization and activity. These interactions are modulated by A-kinase anchoring proteins (AKAPs), which target the PKA subunits to specific subcellular locations, thereby confining PKA activity to particular cellular compartments (Søberg2018The).

The PRKACG subunit is also involved in interactions with proteins that influence platelet function. A study identified a mutation in PRKACG that affects its role in regulating cAMP levels and the phosphorylation of filamin A (FLNa), which is crucial for normal platelet formation and function (Manchev2014A). This mutation leads to defective proplatelet formation, which can be rescued by overexpressing wild-type PRKACG, indicating its interaction with other proteins involved in platelet biogenesis (Manchev2014A).

These interactions highlight the role of PRKACG in cellular signaling pathways, affecting processes like platelet formation and function, and underscore its importance in maintaining cellular homeostasis.


## References


[1. (Manchev2014A) Vladimir T. Manchev, Morgane Hilpert, Eliane Berrou, Ziane Elaib, Achille Aouba, Siham Boukour, Sylvie Souquere, Gerard Pierron, Philippe Rameau, Robert Andrews, François Lanza, Regis Bobe, William Vainchenker, Jean-Philippe Rosa, Marijke Bryckaert, Najet Debili, Remi Favier, and Hana Raslova. A new form of macrothrombocytopenia induced by a germ-line mutation in the prkacg gene. Blood, 124(16):2554–2563, October 2014. URL: http://dx.doi.org/10.1182/blood-2014-01-551820, doi:10.1182/blood-2014-01-551820. This article has 60 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2014-01-551820)

[2. (Søberg2018The) Kristoffer Søberg and Bjørn Steen Skålhegg. The molecular basis for specificity at the level of the protein kinase a catalytic subunit. Frontiers in Endocrinology, September 2018. URL: http://dx.doi.org/10.3389/fendo.2018.00538, doi:10.3389/fendo.2018.00538. This article has 75 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2018.00538)